Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2

• DOI: 10.1021/jacs.3c01421
• Publication Date: 2023-03-28T15:54:00Z
• Authors: Ronan P. Hanley; David Y. Nie; John R. Tabor; Fengling Li; Amin Sobh; Chenxi Xu; Natalie K. Barker; David Dilworth; Taraneh Hajian; Elisa Gibson; Magdalena M. Szew...; Peter J. Brown; Dalia Barsyte-Lov...; Laura E. Herring; Gang Greg Wang; Jonathan D. Licht; Masoud Vedadi; Cheryl H. Arrowsmith; Lindsey I. James
• Keywords: Histones; Gene Expression Regulation; Cell Line, Tumor; Down-Regulation; Chromatin; 3. Good health

Nuclear receptor-binding SET domain-containing 2 (NSD2) plays important roles in gene regulation, largely through its ability to dimethylate lysine 36 of histone 3 (H3K36me2). Despite aberrant activity of NSD2 reported in numerous cancers, efforts to selectively inhibit the catalytic activity of this protein with small molecules have been unsuccessful to date. Here, we report the development of UNC8153, a novel NSD2-targeted degrader that potently and selectively reduces the cellular levels of both NSD2 protein and the H3K36me2 chromatin mark. UNC8153 contains a simple warhead that confers proteasome-dependent degradation of NSD2 through a novel mechanism. Importantly, UNC8153-mediated reduction of H3K36me2 through the degradation of NSD2 results in the downregulation of pathological phenotypes in multiple myeloma cells including mild antiproliferative effects in MM1.S cells containing an activating point mutation and antiadhesive effects in KMS11 cells harboring the t(4;14) translocation that upregulates NSD2 expression.